Chiron's Blood Test Gets Approval

Chiron ( CHIR) said Thursday that the Food and Drug Administration approved its Procleix blood testing system for early detection of a type of HIV and hepatitis C.

Approval of Procleix was expected at the end of last year, but some quality control issues caused a delay. It could have been worse -- some analysts and blood-banking officials had predicted a delay of up to six months.

Procleix, also known as the nucleic acid amplification test, is a super-sensitive screening method that detects at a very early stage the presence of Type 1 HIV and Hepatitis C viruses in donated blood. The system detects these viruses before they would be picked up by other blood-screening methods.

Procleix is already used to screen about 70% of the U.S. blood donations, but until FDA approval, Chiron was only allowed to sell the test at cost.

Chiron was up $1.59, or almost 4%, to $43.22 per share, in recent trading.

More from Opinion

Elon Musk's Latest Twitter Tirade Is the Dumbest Thing on Wall Street

Elon Musk's Latest Twitter Tirade Is the Dumbest Thing on Wall Street

Elon Musk's Twitter Tirade Is the Dumbest Thing on Wall Street

Elon Musk's Twitter Tirade Is the Dumbest Thing on Wall Street

Why Google's Search Momentum Won't Be Badly Hurt by New EU Rules

Why Google's Search Momentum Won't Be Badly Hurt by New EU Rules

Flashback Friday: Amazon, Chip Stocks, Memorial Day

Flashback Friday: Amazon, Chip Stocks, Memorial Day

Time to Talk Tesla: What Happened This Week, Elon?

Time to Talk Tesla: What Happened This Week, Elon?